atropine has been researched along with clomipramine in 25 studies
| Studies (atropine) | Trials (atropine) | Recent Studies (post-2010) (atropine) | Studies (clomipramine) | Trials (clomipramine) | Recent Studies (post-2010) (clomipramine) |
|---|---|---|---|---|---|
| 26,711 | 1,259 | 1,697 | 2,929 | 541 | 304 |
| Protein | Taxonomy | atropine (IC50) | clomipramine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.034 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.071 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.241 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.091 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.005 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.053 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.707 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 3.9465 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.091 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.413 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.005 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0505 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.7065 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.005 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.17 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 1.113 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0678 | |
| Histamine H2 receptor | Homo sapiens (human) | 2.049 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.18 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.067 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.034 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.005 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.035 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.005 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.085 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.139 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.005 | |
| Trypanothione reductase | Trypanosoma brucei brucei | 3.4 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.239 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 0.72 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.245 | |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | 9 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.7615 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.005 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.362 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.005 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (32.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Davies, JA | 1 |
| Ueki, S; Yamamoto, T | 1 |
| Klimek, V; Maj, J; Rawlów, A; Sarnek, J | 1 |
| Billa, JP; Dufour, P; Fabre, J; Roquebert, J | 1 |
| Bennett, JL; Bueding, E; Tomosky, TK | 1 |
| Kocher, R; Rohrer, G | 1 |
| Bräunlich, H; Fleck, C | 1 |
| Núñez, R; Perel, JM | 1 |
| Bizot, JC | 1 |
| Datta, S; Mavanji, V | 1 |
| Gaulier, JM; Lachâtre, G; Marquet, P; Sauvage, FL | 1 |
1 review(s) available for atropine and clomipramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for atropine and clomipramine
| Article | Year |
|---|---|
[Treatment of severe chronic pains with a combination of thymoleptics and neuroleptics (author's transl)].
Topics: Adult; Antidepressive Agents; Atropine; Chlorpromazine; Clinical Trials as Topic; Clomipramine; Drug Combinations; Female; Haloperidol; Humans; Imipramine; Male; Methotrimeprazine; Middle Aged; Morphine; Neoplasms; Pain; Papaverine; Tranquilizing Agents | 1974 |
23 other study(ies) available for atropine and clomipramine
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
The effect of gamma-butyrolactone on locomotor activity in the rat.
Topics: 4-Butyrolactone; Animals; Atropine; Benztropine; Brain Chemistry; Clomipramine; Dopamine; Female; Flupenthixol; Furans; Motor Activity; Pentobarbital; Protriptyline; Rats; Time Factors | 1978 |
Effects of drugs on hyperactivity and aggression induced by raphe lesions in rats.
Topics: 5-Hydroxytryptophan; Aggression; Animals; Atropine; Brain Stem; Clomipramine; Desipramine; Humans; Imipramine; Male; Methyltyrosines; Motor Activity; Raphe Nuclei; Rats | 1978 |
On the anticataleptic action of cyproheptadine.
Topics: Animals; Atropine; Catalepsy; Clomipramine; Cyproheptadine; Desipramine; Female; Fluphenazine; Humans; Imipramine; Male; Methyltyrosines; Pilocarpine; Pimozide; Promethazine; Rats; Reserpine; Spiperone | 1976 |
[Evaluation of the central anticholinergic activity of antidepressants. Comparison of two experimental methods].
Topics: Animals; Antidepressive Agents, Tricyclic; Atropine; Clomipramine; Dibenzazepines; Female; Guinea Pigs; Imipramine; Male; Mice; Mice, Inbred Strains; Oxotremorine; Parasympatholytics; Tremor | 1989 |
Tryptaminergic and dopaminergic responses of Schistosoma mansoni.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atropine; Clomipramine; Dextroamphetamine; Dihydroxyphenylalanine; Ergotamine; Female; Lysergic Acid Diethylamide; Male; Mecamylamine; Motor Activity; Neurotransmitter Agents; Norepinephrine; Reserpine; Schistosoma mansoni; Serotonin; Serotonin Antagonists; Stimulation, Chemical; Synaptic Transmission; Tryptamines; Tyramine | 1974 |
Failure of physostigmine in intoxications with tricyclic antidepressants in rats.
Topics: Animals; Antidepressive Agents, Tricyclic; Atropine; Clomipramine; Desipramine; Drug Interactions; Female; Heart Rate; Imipramine; Lethal Dose 50; Physostigmine; Rats; Rats, Inbred Strains; Respiration; Time Factors | 1982 |
Comparative neurotransmitter reuptake and anticholinergic potencies of the 8-hydroxy metabolites of clomipramine.
Topics: Animals; Antidepressive Agents; Atropine; Clomipramine; Dose-Response Relationship, Drug; Male; Neurotransmitter Agents; Rats; Rats, Sprague-Dawley; Serotonin | 1995 |
Effects of psychoactive drugs on temporal discrimination in rats.
Topics: Animals; Atropine; Clomipramine; Desipramine; Diazepam; Discrimination Learning; Discrimination, Psychological; Haloperidol; Male; Nicotine; Psychotropic Drugs; Rats; Rats, Wistar; Scopolamine | 1997 |
Sleep-wake effects of yohimbine and atropine in rats with a clomipramine-based model of depression.
Topics: Acetylcholine; Adrenergic alpha-Agonists; Aggression; Animals; Animals, Newborn; Antidepressive Agents, Tricyclic; Atropine; Brain; Brain Chemistry; Clomipramine; Depressive Disorder; Disease Models, Animal; Injections, Intraventricular; Male; Muscarinic Antagonists; Norepinephrine; Rats; Rats, Wistar; Reaction Time; Sleep Wake Disorders; Sleep, REM; Wakefulness; Yohimbine | 2002 |
Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis.
Topics: Atropine; Chromatography, Liquid; Clomipramine; Humans; Lysergic Acid Diethylamide; Molecular Structure; Pharmaceutical Preparations; Phenothiazines; Tandem Mass Spectrometry | 2008 |